Nuvectis Pharma, Inc. (NVCT) company profile

Nuvectis Pharma is a clinical-stage biopharmaceutical company that develops precision therapeutics for serious cancer conditions. Its lead product candidate is NXP900, an oral small-molecule targeted inhibitor of SRC and YES1 kinases currently evaluated in clinical trials for advanced solid tumors. The firm previously evaluated another oncology candidate, NXP800, before halting its clinical development. As an early-stage development business with no commercialized treatments, the company does not operate commercial sales segments or serve end consumers; its drug candidates are tested in cancer patients enrolled in clinical trials.

The company maintains its executive office in Fort Lee, New Jersey. Nuvectis owns no manufacturing plants, instead relying on single-source third parties to manufacture drug substances and finished products for clinical testing. The company holds exclusive global commercial rights to its primary drug candidate under a license from Scotland, with intellectual property protections spanning the United States, the European Union, China, Japan, and Canada.

Summary of the business section of Nuvectis Pharma's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“We are offering 3,200,000 shares of our common stock at an offering price of $5.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of February 6, 2026, we had 13 full-time employees.”